FAST-EU Trial 6 Month Results Published in Gynecological Surgery; 12 Month Results presented at 43rd Annual AAGL Meeting. REDWOOD CITY, CA – December 9, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
FDA Grants Approval To Commence SONATA Pivotal IDE Clinical Trial
Distinct Alternative to Surgery, Radiological Approaches and Power Morcellation, for the Treatment of Symptomatic Uterine Fibroids. REDWOOD CITY, CA – October 22, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic
Gynesonics Names Richard P. Lanigan as Vice President, Global Commercialization
Veteran Medical Device Executive with Expertise in Clinical, Reimbursement, Sales, Marketing REDWOOD CITY, CA – August 7, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced it has
Gynesonics Announces First Patient Successfully Treated with VizAbate System
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company’s newly-designed
Gynesonics Inc. Received CE Mark Approval for its Next Generation VizAblate® System Enabling Use Throughout the European Union
The Only System to Combine and Integrate Ultrasound Imaging with Radiofrequency Ablation in a Single Device June 12, 2014 10:00 AM Eastern Daylight Time REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company that has developed a minimally invasive device
Gynesonics Inc. Announces the Appointment of Christopher M. Owens to President and Chief Executive Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that it has named veteran medical device executive Christopher M. Owens as President and Chief Executive
Gynesonics, Inc. Announced a Series D Financing Led By HBM Partners
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, announced today a Series D financing led by HBM Partners based in Switzerland. The $21 million financing included additional new investor